Insilico Medicine announces new AI collaboration with CTFH

Michael Walter | | Health Exec | Precision Medicine

Insilico Medicine, a Hong Kong-based AI company, has announced a new collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) aimed at improving care for breast cancer patients.

CTFH, a pharmaceutical company known for adopting advanced technologies, is a joint venture between the Chia-Tai Group and Jiangsu Agriculture Reclamation Group. The work by Insilico Medicine and CTFH will be focused on accelerating “drug discovery and development with an AI-enabled platform for triple-negative breast cancer.”

“We look forward to a long-term partnership with Insilico Medicine,” Wenyu Xia, general manager of CTFH, said in a prepared statement. “As the premier AI drug discovery company in the industry, Insilico Medicine has demonstrated capabilities to generate novel molecules with specified properties using its next-generation AI platform. We believe that this collaboration will speed up the R&D process, reduce the cost and provide greater benefits to patients.”

Insilico Medicine could receive up to $200 million for its efforts if certain key milestones are reached.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”